FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1072-1073 September 4, 2008 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Weiner, L. M. Related Article by Hunder, N. N. Related Article by Finn, O. J. PubMed Citation

To the Editor: In his review of cancer immunology, Finn (June 19 issue)¹ states that the results of immunotherapy involving intravenous administration of tumor-specific autologous T cells (adoptive cell therapy) are "marginal," whereas the results of trials of cancer vaccines are "encouraging." We do not believe this conclusion accurately reflects the state of the field.

In 1994, we reported a 34% objective response rate among patients with metastatic melanoma who were treated with adoptive cell therapy.² These results have steadily improved. Adding lymphocyte-depleting chemotherapy before adoptive cell therapy increased the objective-response rate to 49%,³ and adding radiotherapy increased the objective-response . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.